Morepen Lab -Q2FY19

1. Net Revenue up by 15% at Rs. 173.93 cr backed by improved sales revenue from Home
2. Diagnostics and Formulations. Export sales up by 38 % at Rs. 65.05 cr
3. Loratadine records remarkable growth amongst bulk drugs in the quarter @29%: 31% growth in
4. the export on Y-o-Y basis. Atorvastatin sales have grown by 40%; Export turnover jumps by 46%
5. Blood Glucose Monitors’ quarterly sales increased by 38% & Nebulisers’ by 131%. Overall
6. Diagnostic Devises sales grew by 25% in Q2'FY19.
7. Dr. Morepen Basket quarterly sales have recorded a growth of 33% in the branded OTC
8. category.
9. Interest Cost falls further by 76% from 1.31 cr in Q1 FY 2017-18 to Rs. 0.32 cr only in
10. Q2’FY19.